Pharmaforce

Pharmaforce provides companies with the professional expertise they need for their business to succeed. We are a leading supplier of Contract Sales Outsourcing, Commercial, and HR & Recruitment Services. We have been working with companies in the Pharmaceutical, MedTech and Healthcare sectors across Ireland for over 10 years. Pharmaforce is part of the award winning Pharmed Group, a wholly owned Irish company and leading healthcare and pharmaceutical services provider across Ireland and the UK, with established networks throughout Europe.

Related News

CELL AND GENE THERAPY

MISSION BIO AND S2 GENOMICS TO PROVIDE TUMOR SAMPLE FOR SINGLE-CELL DNA ANALYSIS

Mission Bio | April 20, 2022

news image

Mission Bio, Inc., a leader in high-throughput single-cell DNA and multi-omics analysis, announced today a co-marketing agreement with S2 Genomics, Inc., a leading developer of laboratory automation solutions for processing solid tissues for single-cell applications, to provide a single streamlined workflow for solid tumor applications from sample prep to analysis. Christine A. Iacobuzio-Donahue, MD, Ph.D., Director of the Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer ...

Read More

DIAGNOSTICS

VERISIM LIFE AND TOTAL BRAIN ANNOUNCE STRATEGIC COLLABORATION AGREEMENT APPLYING AI TO DEVELOP NEW DRUGS FOR NEUROLOGICAL DISORDERS

VeriSIM Life | May 30, 2022

news image

VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain www.totalbrain.com, an applied, integrative neuroscience company, to create breakthrough neurodata-driven actionable insights for developing novel drugs to treat a wide range of neurological disorders. The partnership will pioneer the integration of Total Bra...

Read More

CELL AND GENE THERAPY

SHORELINE BIOSCIENCES ANNOUNCES $140M FINANCING TO ADVANCE PIPELINE OF NEXT GENERATION CELL IMMUNOTHERAPIES

Shoreline Biosciences | November 02, 2021

news image

Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapies, today announced the completion of a $140M financing, led by Ally Bridge Group, with participation from new investors Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, and Supers...

Read More

INDUSTRIAL IMPACT

MCMASTER, SARTORIUS STEDIM BIOTECH TEAM UP TO ADVANCE BIOMANUFACTURING PROCESSES WITH NEXT-GEN TECH

Sartorius Stedim Biotech S.A | August 23, 2021

news image

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has entered into a partnership with McMaster University to improve manufacturing processes of antibody and virus-based treatments for diseases such as COVID-19, cancers, and genetic disorders. Using a state-of-the-art multi-column chromatography system provided by Sartorius Stedim Biotech, the McMaster team will "perfect" a process for the purification of therapeutic viruses that...

Read More
news image

CELL AND GENE THERAPY

MISSION BIO AND S2 GENOMICS TO PROVIDE TUMOR SAMPLE FOR SINGLE-CELL DNA ANALYSIS

Mission Bio | April 20, 2022

Mission Bio, Inc., a leader in high-throughput single-cell DNA and multi-omics analysis, announced today a co-marketing agreement with S2 Genomics, Inc., a leading developer of laboratory automation solutions for processing solid tissues for single-cell applications, to provide a single streamlined workflow for solid tumor applications from sample prep to analysis. Christine A. Iacobuzio-Donahue, MD, Ph.D., Director of the Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer ...

Read More
news image

DIAGNOSTICS

VERISIM LIFE AND TOTAL BRAIN ANNOUNCE STRATEGIC COLLABORATION AGREEMENT APPLYING AI TO DEVELOP NEW DRUGS FOR NEUROLOGICAL DISORDERS

VeriSIM Life | May 30, 2022

VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain www.totalbrain.com, an applied, integrative neuroscience company, to create breakthrough neurodata-driven actionable insights for developing novel drugs to treat a wide range of neurological disorders. The partnership will pioneer the integration of Total Bra...

Read More
news image

CELL AND GENE THERAPY

SHORELINE BIOSCIENCES ANNOUNCES $140M FINANCING TO ADVANCE PIPELINE OF NEXT GENERATION CELL IMMUNOTHERAPIES

Shoreline Biosciences | November 02, 2021

Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapies, today announced the completion of a $140M financing, led by Ally Bridge Group, with participation from new investors Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, and Supers...

Read More
news image

INDUSTRIAL IMPACT

MCMASTER, SARTORIUS STEDIM BIOTECH TEAM UP TO ADVANCE BIOMANUFACTURING PROCESSES WITH NEXT-GEN TECH

Sartorius Stedim Biotech S.A | August 23, 2021

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has entered into a partnership with McMaster University to improve manufacturing processes of antibody and virus-based treatments for diseases such as COVID-19, cancers, and genetic disorders. Using a state-of-the-art multi-column chromatography system provided by Sartorius Stedim Biotech, the McMaster team will "perfect" a process for the purification of therapeutic viruses that...

Read More